NCT00667862View on ClinicalTrials.gov

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 18, 2008

Primary Completion Date

November 5, 2010

Study Completion Date

November 5, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Panobinostat

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

21201

University of Maryland, Baltimore

21287

Johns Hopkins Hospital, Baltimore

63130

Washington University, St Louis

53706-1481

University of Wisconsin, Madison

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY